Elly Gerald Stoica

Array ( [id] => 17243503 [patent_doc_number] => 20210363246 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => Method of Modulating Autoimmunity by Disrupting cis-Ligand Binding of Siglec Type Antigens [patent_app_type] => utility [patent_app_number] => 17/283693 [patent_app_country] => US [patent_app_date] => 2019-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30296 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283693 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15493257 [patent_doc_number] => 20200046817 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => NEOEPITOPE VACCINE AND IMMUNE STIMULANT COMBINATIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 16/656293 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13281 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16656293 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15800207 [patent_doc_number] => 20200123246 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => INHIBITING GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR (GM-CSF) PREVENTS PRETERM BIRTH [patent_app_type] => utility [patent_app_number] => 16/655733 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7029 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16655733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15800207 [patent_doc_number] => 20200123246 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => INHIBITING GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR (GM-CSF) PREVENTS PRETERM BIRTH [patent_app_type] => utility [patent_app_number] => 16/655733 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7029 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16655733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15711233 [patent_doc_number] => 20200102382 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => Compositions And Methods For Treating Cancer [patent_app_type] => utility [patent_app_number] => 16/601140 [patent_app_country] => US [patent_app_date] => 2019-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21921 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16601140 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15866253 [patent_doc_number] => 20200140530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => ANTI-LAP ANTIBODY VARIANTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/597593 [patent_app_country] => US [patent_app_date] => 2019-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71609 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16597593 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336039 [patent_doc_number] => 20220002370 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => MASKED CYTOKINE POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 17/279407 [patent_app_country] => US [patent_app_date] => 2019-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 156840 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17279407 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283787 [patent_doc_number] => 20200277389 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => METHOD OF TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE LEUKEMIA [patent_app_type] => utility [patent_app_number] => 16/580012 [patent_app_country] => US [patent_app_date] => 2019-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8312 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16580012 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16525280 [patent_doc_number] => 20200399360 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => ANTI-CXCL13 ANTIBODIES FOR TREATING AUTOIMMUNE DISEASES AND CANCER [patent_app_type] => utility [patent_app_number] => 16/963130 [patent_app_country] => US [patent_app_date] => 2019-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19396 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16963130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19840173 [patent_doc_number] => 12252542 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Anti-CD137 antibodies and method of treating colorectal cancer using them [patent_app_type] => utility [patent_app_number] => 17/285760 [patent_app_country] => US [patent_app_date] => 2019-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 21 [patent_no_of_words] => 17010 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17110080 [patent_doc_number] => 20210290677 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST [patent_app_type] => utility [patent_app_number] => 17/274167 [patent_app_country] => US [patent_app_date] => 2019-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49900 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -73 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17274167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156163 [patent_doc_number] => 20210317214 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => COMBINATION THERAPY OF A PD-1 ANTAGONIST AND LAG3 ANTAGONIST FOR TREATING PATIENTS WITH NON-MICROSATELLITE INSTABILITY-HIGH OR PROFICIENT MISMATCH REPAIR COLORECTAL CANCER [patent_app_type] => utility [patent_app_number] => 17/274531 [patent_app_country] => US [patent_app_date] => 2019-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17939 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17274531 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20127963 [patent_doc_number] => 12370263 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Cyclic dinucleotide derivative based antibody-drug conjugates [patent_app_type] => utility [patent_app_number] => 17/273666 [patent_app_country] => US [patent_app_date] => 2019-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 35 [patent_no_of_words] => 113230 [patent_no_of_claims] => 73 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 628 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17273666 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17126250 [patent_doc_number] => 20210301018 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/273955 [patent_app_country] => US [patent_app_date] => 2019-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64065 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17273955 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15866213 [patent_doc_number] => 20200140510 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => GITRL FUSION PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/559152 [patent_app_country] => US [patent_app_date] => 2019-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34598 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16559152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17895398 [patent_doc_number] => 20220305060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => METHOD FOR PREPARING IMMUNE-TOLERIZED EXTRACELLULAR VESICLE CONTAINING LACTATE DEHYDROGENASE B AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA, AND ANTI-CANCER COMPOSITION USING EXTRACELLULAR VESICLE [patent_app_type] => utility [patent_app_number] => 17/611046 [patent_app_country] => US [patent_app_date] => 2019-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8812 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17611046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17162985 [patent_doc_number] => 11149072 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-19 [patent_title] => Variant survivin vaccine for treatment of myeloma [patent_app_type] => utility [patent_app_number] => 16/548989 [patent_app_country] => US [patent_app_date] => 2019-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 39 [patent_no_of_words] => 33664 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16548989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17664150 [patent_doc_number] => 11357826 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-14 [patent_title] => IL-10 EGFR antibody fusion protein and uses thereof [patent_app_type] => utility [patent_app_number] => 16/547158 [patent_app_country] => US [patent_app_date] => 2019-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 33339 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16547158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17207781 [patent_doc_number] => 11168140 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-09 [patent_title] => Anti-IL1RAP antibodies [patent_app_type] => utility [patent_app_number] => 16/541990 [patent_app_country] => US [patent_app_date] => 2019-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 48 [patent_no_of_words] => 50942 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16541990 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15254219 [patent_doc_number] => 20190375843 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES [patent_app_type] => utility [patent_app_number] => 16/540819 [patent_app_country] => US [patent_app_date] => 2019-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56874 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16540819 [rel_patent_id] =>[rel_patent_doc_number] =>)